Order of the National Green Tribunal in the matter of News Item titled "2 killed in blast at illegal cracker unit in Thanjavur appearing in The Hindu dated 19.05.2025". The application is registered suo-motu on the basis of the news item titled 2 killed in blast at illegal cracker unit …
After consecutive litigation losses against Pfizer in its bid to grab a market share of the world's largest selling drug, Lipitor, Ranbaxy can now breathe easy. Last week, the Indian company got a shot in the arm, with the US Patent and Trademark Office (USPTO) issuing a a preliminary rejection …
Dora Akunyili is director-general of Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC). Since her appointment in 2001, she has led a successful crusade against counterfeit pharmaceuticals, which are responsible for millions of deaths worldwide each year.
Ranbaxy on Tuesday said that it has entered into a business alliance with Orchid Chemicals & Pharmaceuticals, involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients (raw materials). However, sources said the option of acquiring additional equity in Orchid, and announcing an open offer at …
Ranbaxy Laboratories (Ranbaxy) and Orchid Chemicals & Pharmaceuticals (Orchid) have announced that they have entered into a business alliance agreement involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients (APIs). Additionally, this agreement would establish a framework for enhanced future co-operation between the two companies. …
A parliamentary panel has pulled up the Department of Chemicals and Petrochemicals for delay in finalising the National Pharmaceutical Policy, 2006. In its report, the Parliamentary Standing Committee on Chemicals and Fertilizers has observed that despite its recommendation for finalising the policy, the department remained static on such a crucial …
The Parliamentary Standing Committee on Chemical and Fertiliser has slammed the Department of Chemicals and Petrochemicals over the delay in finalising National Pharmaceutical Policy (NPP) 2006. The policy, aimed at making drugs cheaper, has been delayed due to strong opposition from the industry. While the policy will bring more number …
Clinical research organisation Siro Clinpharm Pvt Ltd has acquired 100 per cent equity in Germany-based Omega Mediation Group in an all-cash deal, but for an undisclosed sum. The acquisition marks Siro Clinpharm's entry into Europe, said Dr Chetan Tamhankar, Chief Operating Officer, Siro Clinpharm. Omega has around 120 people, across …
Sixteen months after it was set up, an inter-ministerial group is set to finalise a new pharma policy for the country. A group of ministers (GoM) headed by Agriculture Minister Sharad Pawar is scheduled to meet on April 30 to finalise its recommendations for a policy that would attempt to …
Ranbaxy is understood to be finalizing a plan to announce an open offer for Chennai-based Orchid Chemicals. Solrex, believed to be backed by Ranbaxy's promoters, has already bought 11.3% stake in Orchid, and according to market sources, later upped it to 14.7%. This is marginally less than the 15% limit …
The country's largest drug maker Ranbaxy Laboratories today announced the launch of bonista teriparatide injection used in the treatment of osteoporosis (thinning of bones) in collaboration with Hyderabad-based Virchow Biotech. Ranbaxy has become the first company in the world to launch this bio-generic product, the company said in a filing …
Country's largest drug maker, Ranbaxy, on Thursday announced the launch of 'BONISTA- Teriparatide' injection used in the treatment of Osteoporosis disease in collaboration with Hyderabad-based Virchow Biotech. BONISTA- Teriparatide injection is manufactured by recombinant human parathyroid hormone and Ranbaxy has become first company in the world to launch this bio-generic …
MP's small and medium drug manufacturers, which are mainly located in Indore and Pithampur, are crying themselves hoarse due to the huge business losses being incurred due to non clearance and non-approvals from the drug controller's department. The post of the drug controller has been lying vacant for the last …
In a move likely to influence future drug price regulation in the country, the National Pharmaceutical Pricing Authority (NPPA) has started a process to understand how other countries carry out this function. The authority has already studied the relevant regulatory systems in at least eight major countries. It has also …
Justice S Ravinder Bhat of the Delhi High Court is a hero to some. His decision last month to allow generic drug manufacturer Cipla to continue manufacturing its version of Roche's patented lung cancer drug erlotinib (sold as Tarceva in India) has made him the toast of public health activists …
Novartis India is up in arms against a two-month old decision of the National Pharmaceutical Pricing Authority (NPPA) to reduce the price of its flagship brand Voveran on public interest grounds. The annual sales of Voveran, the brand name for pain reliever medicine diclofenac, exceed Rs 100 crore and account …
The lead outside investigator on a crucial trial of two widely used anti-cholesterol drugs said in an e-mail message in July that Merck and Schering-Plough, the companies that make the drugs, were deliberately delaying the release of the trial results "to hide something." The companies did not release the preliminary …
Currently, there is a debate on what impact the implementation of the Trade Related Aspects of Intellectual Property Rights (TRIPS) in India would have on its pharmaceutical industry and health care. The debate hinges primarily on two major questions. First, will the new patent regime provide an impetus for innovation …
pharmaceutical giant GlaxoSmithKline is recalling its malaria drug Lapdap and has discontinued development of another malaria drug, Dacart, saying the drugs can lead to anaemia in some patients. Experts say the move is a setback to fight the disease. On February 29, Glaxo said its clinical trials had found that …
The Special Economic Zone (SEZ) imbroglio in Goa has taken a legal turn. Meditab Specialities Pvt Ltd, developer of the SEZ in Goa where Cipla was to set up its plant, has filed a petition at the Goa Bench of the Bombay High Court challenging the Goa Government on its …
